Organization


MOLECULAR BIOMEDICINE PROGRAM Department - Riyadh

5801

 

Overview

The objective of the Molecular BioMedicine Program is to investigate mechanisms of diseases and develop necessary tools with potential translational outcome in therapy or in medical biotechnology. The program currently focuses on a medically important family of genes associated with regulating mRNA stability and translation which are perturbed as a result of disease. The program has a unique and internationally known research platform which is applicable to the study of several chronic disease conditions including inflammatory, infectious, and cancer states.

Achievements

Projects

  • Post-transcriptional control of gene expression: screening of drug-like compounds and modulation in cancer cells
  • Post-transcriptional host response to intracellular bacterial pathogens.
  • The AU-rich interactome in cancer
  • The effect of cytokinome on interferon response

Sections

  • Interferons and Cytokines
  •  Disease System Biology
  •  Translational Biotechnology

Patents

  1. EU Patent. 2004. METHOD OF GENERATING TRANSLATIONALLY ACTIVE LINEAR DNA MOLECULES AND USE THEREOF IN ARRAY FORMATS.
  2. EU Patent. 2005. HYBRID 3’ UNTRANSLATED REGIONS SUITABLE FOR EFFICIENT PROTEIN EXPRESSION IN MAMMALIAN CELLS.
  3. GCC patent. 2006. HYBRID 3’ UNTRANSLATED REGIONS SUITABLE FOR EFFICIENT PROTEIN EXPRESSION IN MAMMALIAN CELLS.
  4. U.S. Patent. 8,790,896 “A METHOD FOR INCREASING PROTEIN EXPRESSION IN EUKARYOTIC CELLS”. Filed: 2010. Granted: 2014.
  5. U.S. Patent. 8,795,962. Expression vectors based on modified ribosomal protein promoters and uses thereof in post-transcriptional assessment. Filed: 2008. Granted: 2014.
  6. U.S. Patent. 8,791,241. International Patent Application. "FLUORESCENT PROTEINS WITH INCREASED ACTIVITY IN CELLS”. Filed: 2010. Granted: 2014.
  7. U.S. Patent. 8,680,256. Methods for producing inducible and/or repressible expression active linear RNA interference cassettes and inducible and/or repressible expression active linear gene cassettes and their uses. Filed: 2009. Granted: 2014
  8. EU Patent. EP2307567. Methods for producing inducible and/or repressible expression active linear RNA interference cassettes and inducible and/or repressible expression active linear gene cassettes and their uses. Filed: 2009. Granted: 2014
  9. U.S. Patent. US20090181427. Hybrid 3′ untranslated regions suitable for efficient protein expression in mammalian cells. Filed: 2009. Issued: 2005

Program Director:

Khalid s. Abu Khabar, Ph.D.

Deputy Executive Director, Research Centre

Director, Molecular BioMedine Program

King Faisal Specialist Hospital & Research Centre

Biography

Dr. Khabar obtained his M.Sc. in Microbial Kinetics at University of Illinois, USA and his Ph.D. in Molecular Immunology at University of Pittsburgh Pittsburgh, PA, USA. He holds an appointment as Adjunct Staff at the Department of Cancer Biology, Lerner Research Institute and Cleveland Clinic Foundation. Recipient of the U.S. National Delta Omega Honor, International Cancer Technology Transfer Award from the International Union Against Cancer (UICC) in 2000. Recipient of the first Outstanding Scientist Award in KFSHRC 2002 and several Research Achievement Awards from KFSH&RC. Recipient of the Crown Prince-sponsored Tomorrow Award (2010) and the King’s award for inventors and talents (2012).  Published over 60 peer-reviewed full-length papers including five invited reviews on cytokines, interferons, and functional genomics. Principal Investigator on competitive local institutional grants. Co-investigator or Collaborator on a number of international grants including NIH sub-contract. Active reviewer/editor/guest editor for several U.S. and international journals in the cytokine and RNA stability field. Invited for lectures in national and international academic institutions and conference plenary sessions. Member or board member of several National Biotechnology development committees. Have more than 15 patents and patent applications in Molecular biology and functional genomics.

Recent Selected Publications

For complete list, see the link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Khabar+K

  1. Al-Ahmadi, W, Al-Ghamdi, M., Al-Haj, L., and K S. A. Khabar*. 2009. Alternative Polyadenylation Variants of the RNA Binding Protein, HuR: Abundance and Role of AU-rich Elements. Nucleic Acids Research. 37(11):3612-24.
  2. Hitti E, Al-Yahya S, Al-Saif M, Mohideen P, Mahmoud L, Polyak SJ, Khabar* 2010 A versatile ribosomal protein promoter-based reporter system for selective assessment of RNA stability and post-transcriptional control. RNA. 16(6):1245-55.
  3. Khabar* 2010. Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. Cell Mol Life Sci. 67(17):2937-55. Invited Review.
  4. Al-Souhibani N, Al-Ahmadi W, Hesketh JE, Blackshear PJ, Khabar* KS. The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes. Oncogene. 9(29):4205-15.
  5. Halees AS, Hitti E, Al-Saif M, Mahmoud L, Vlasova-St Louis IA, Beisang DJ, Bohjanen PR, Khabar* K. 2011. Global assessment of GU-rich regulatory content and function in the human transcriptome. RNA Biol. 18(4):681-91.
  6.  Mahmoud L, Al-Saif M, Amer HM, Sheikh M, Almajhdi FN, Khabar* KS. 2011. Green fluorescent protein reporter system with transcriptional sequence heterogeneity for monitoring the interferon response. J Virol. 85(18):9268-75.
  7. Al-Saif M, Khabar* KS. 2012. UU/UA Dinucleotide Frequency Reduction in Coding Regions Results in Increased mRNA Stability and Protein Expression. Mol Ther 20(5):954-9.
  8. Al-Haj L, Blackshear PJ, Khabar* KS. 2012. Regulation of p21/CIP1/WAF-1 mediated cell-cycle arrest by RNase L and tristetraprolin, and involvement of AU-rich elements. Nucleic Acids Res. 40(16):7739-52.
  9. Al-Ahmadi W, Al-Ghamdi M, Al-Souhibani N, Khabar KS*. 2013. miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J. Pathology. 230(1):28-38.
  10. Mahmoud L, Al-Enezi F, Al-Saif M, Warsy A, Khabar KS*, Hitti EG. 2014. Sustained stabilization of Interleukin-8 mRNA in human macrophages. RNA Biology. 11(2):124-33.
  11. Al-Souhibani N, Al-Ghamdi M, Al-Ahmadi W, Khabar KS*. 2014. Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells. Carcinogenesis.
  12. Khabar* KS. 2014. Post-transcriptional control of cytokine gene expression in health and disease. J Interferon Cytokine Res. 34(4):215-9. Issue Guest Editorial.
  13. Al-Yahya S, Mahmoud L, Al-Zoghaibi F, Al-Tuhami A, Amer H, Almajhdi FN, Polyak SJ, Khabar KS.  Human Cytokinome Analysis for Interferon Response. J Virology. 2015 Jul;89(14):7108-19.
  14. Hitti, E., T. Bakheet, N. Al-Souhibani, W. Moghrabi, S. Al-Yahya, M. Al-Ghamdi, M. Al-Saif, M. M. Shoukri, A. Lánczk, R. Grepin, B. Gy?rffy, G. Pagès and K. S. A. Khabar (2016). "Systematic analysis of AU-rich element expression in cancer reveals common functional clusters regulated by key RNA-binding proteins." Cancer Research

Gallery

Accreditations & Awards